$NAUT

AH Equity Partners Bio II, L.L.C. sold $10.8M of NAUT (indirect holdings)

AH Equity Partners Bio II, L.L.C. sold 4,615,974 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($10.85M total) on 2026-06-02.

Original reporting
SEC EDGAR · AH Equity Partners Bio II, L.L.C.
Published Jun 4, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NAUT
Bearish
medium confidence
Mentioned
$NAUT
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NAUTBearishMed
01

Why it matters

The key new information is the disclosed sale size, price, and post-transaction holdings, which can influence short-term sentiment and trading positioning.

02

Market read

Large disclosed selling by a major holder can create a near-term overhang, especially in thinly traded biotech names.

03

What to watch

Form 4s often lag actual trading; without context on total position changes over time, the market may overreact to a single transaction size.

Relevance 8/10Novelty 7/10Timing: After-hours/next-session read-through from a June 2 Form 4 filed June 4

Background

This is an SEC Form 4 insider transaction disclosure by a 10% owner (AH Equity Partners Bio II, L.L.C.) for Nautilus Biotechnology.

Company-level read

Ticker impact

$NAUTBearishMedium confidence
Context

Nautilus Biotechnology disclosed a 10% owner open-market sale of 4,615,974 shares at $2.35 on June 2 via an SEC Form 4.

Expected impact

Near-term sentiment drag possible; magnitude likely limited unless follow-on selling accelerates or coincides with other catalysts.

Evidence & confidence

The filing is a disclosed ownership reduction (open-market S) with no 10b5-1 plan and a large share count, which markets may interpret as increased risk or liquidity needs.

Market effects

For biotech microcaps, large insider/major-holder sales can raise perceived binary-risk and liquidity concerns across similar names.

No clear regional spillover indicated; this is company-specific insider activity.

Limited global relevance; primarily affects NAUT’s shareholder sentiment and near-term trading flow.

Counterpoint

Absence of a 10b5-1 plan does not automatically imply negative fundamentals; the sale could be pre-planned for diversification/taxes or unrelated to business outlook.

Key entities

  • Nautilus Biotechnology, Inc.

    Subject of the Form 4 insider transaction; 10%-owner sold 4,615,974 shares at $2.35.

  • AH Equity Partners Bio II, L.L.C.

    Reporter of the open-market sale; holdings after transaction reported as 11,682,032 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NAUTMed

Nautilus Biotechnology, Inc. (NAUT): Results of Operations and Financial Condition

Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,